- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05018416
Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
A Phase 2, Randomized, Open-Labeled, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
Study Overview
Status
Intervention / Treatment
Detailed Description
The objective of this study is to assess the safety, efficacy, and durability of up to two REACT injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with T1DM or T2DM and CKD:
- Cohort 1: Two scheduled REACT injections given 3 months (+60 days) with at least 18- month follow-up
- Cohort 2: One scheduled REACT injection with a possible second REACT injection, no less than 3 months after the first one, within 30 days (+30 days) of meeting a renal function redose trigger (triggered up to 15 months following the first REACT injection).
Both cohorts will be followed for 18 months after the final REACT injection. If a Cohort 2 subject does not meet a trigger, the subject will be followed for at least 18 months after the first injection.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tierney Daigle
- Phone Number: 336-448-2843
- Email: tierney.daigle@prokidney.com
Study Contact Backup
- Name: Patricia Yen
- Email: patricia.yen@ppd.com
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80210-5073
- Kidney Associates of Colorado, P.C. - Frenova
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Nephrology Associates
-
-
Idaho
-
Nampa, Idaho, United States, 83687
- Boise Kidney and Hypertension Institute - Frenova
-
-
Michigan
-
Kalamazoo, Michigan, United States, 49007-3889
- Paragon Health, PC d/b/a Nephrology Center, PC - Frenova
-
-
Mississippi
-
Tupelo, Mississippi, United States, 38801-6560
- Nephrology and Hypertension Associates Ltd - Frenova
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged 30 to 80 years, inclusive, on the date informed consent is signed.
- Clinical diagnosis of T1DM or T2DM, controlled per institutional standard of care.
- The subject has a clinical diagnosis of diabetic nephropathy as the underlying cause of renal disease (diagnosis does not have to be confirmed via renal biopsy).
- The subject has a serum glycosylated hemoglobin (HbA1c) level less than 10% at the Screening Visit.
- The subject has a documented clinical diagnosis of an eGFR between 20 and 50 mL/min/1.73m² inclusive not requiring renal dialysis.
Exclusion Criteria:
- The subject has a history of renal transplantation.
The subject has a mean systolic blood pressure greater than or equal to 140 mmHg and/or mean diastolic blood pressure greater than or equal to 90 mmHg at screening.
Subjects with blood pressure outside of this range prior to biopsy/injection may continue if approved by the Medical Monitor.
- The subject has hemoglobin levels less than 10 g/dL and is not responsive to the standard medical intervention for CKD-related anemia prior to randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2 REACT injections
Cohort 1 subjects will receive 2 REACT injections in the biopsied and non-biopsied contralateral kidneys 3 months apart (+60 days).
|
Autologous selected renal cells (SRC)
|
Experimental: 1 REACT Injection
Cohort 2 subjects will receive 1 REACT injection into the biopsied kidney and if a pre-defined trigger is met, will undergo a second REACT injection into the contralateral kidney.
|
Autologous selected renal cells (SRC)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equation
Time Frame: Screening thru month 28
|
Screening thru month 28
|
Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.
Time Frame: Screening thru 18 months after the last injection of study drug
|
Screening thru 18 months after the last injection of study drug
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ashley Johns, Prokidney
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Endocrine System Diseases
- Disease Attributes
- Renal Insufficiency
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Kidney Diseases
- Renal Insufficiency, Chronic
- Diabetes Mellitus, Type 1
Other Study ID Numbers
- REGEN-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
Clinical Trials on Renal Autologous Cell Therapy (REACT)
-
ProkidneyRecruitingChronic Kidney Diseases | Diabetic Kidney DiseaseUnited States
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedChronic Kidney Disease | Congenital Anomalies of Kidney and Urinary TractUnited States
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States
-
ProkidneyRecruitingChronic Kidney Diseases | Diabetic Kidney Disease | CAKUTUnited States
-
ProkidneyIqvia Pty LtdNot yet recruitingChronic Kidney Diseases | Type 2 Diabetes Mellitus
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States
-
ProkidneyPPD; Iqvia Pty LtdActive, not recruitingChronic Kidney Diseases | Type 2 Diabetes MellitusUnited States, United Kingdom, Taiwan, Australia, Canada
-
Dr. Grant M. PagdinRecruitingOsteoarthritisCanada
-
Hospitales NisaUniversitat Politècnica de ValènciaCompletedStroke | Hemiparesis | Chronic Stroke | Upper Limb InjurySpain
-
University of Alabama at BirminghamCompleted